Oncology immunotherapy & pipeline momentum (vaccines, CARs, RAS, MRD, ADCs, RNA, bispecifics, MM quads; prostate/endometrial/uveal/bladder/H&N/RCC/brain/mel/HER2/gastric/GEJ/NSCLC/pancreatic/HCC/TNBC/KRAS/SCLC; PORTEC-4a, proton, TILs, CD70 CAR-T, durva, HIF dual, RIBOTAC, EMERALD-3, gotistobart, teclistamab/dara/IsKia)
Key Questions
What were the key results from the EMERALD-3 trial in hepatocellular carcinoma (HCC)?
The Phase 3 EMERALD-3 trial showed a progression-free survival (PFS) win for durvalumab and tremelimumab combined with lenvatinib and TACE in HCC patients. AstraZeneca reported positive high-level results from this study evaluating immunotherapy plus targeted therapy and embolization.
How did teclistamab plus daratumumab perform in the MajesTEC-3 trial for multiple myeloma?
In MajesTEC-3, teclistamab combined with daratumumab achieved a hazard ratio of 0.17 and 83% 3-year survival in relapsed/refractory multiple myeloma (RRMM). This combination is considered one of the most exciting options for R/R MM patients.
What are the results of gotistobart in pretreated NSCLC patients?
Gotistobart, an anti-CTLA-4 therapy, showed promise in Phase 3 for squamous NSCLC with overall response rate (ORR) of 20% and non-reached overall survival (OS). It demonstrated improved outcomes in pretreated patients.
What efficacy was seen with subcutaneous amivantamab in NSCLC?
Subcutaneous amivantamab in EGFR+ NSCLC achieved an 85% ORR, comparable to prior intravenous reports from the PALOMA-2 trial. This formulation represents a way to advance care in NSCLC.
Does the timing of immunotherapy affect outcomes in small cell lung cancer (SCLC)?
Administering immunotherapy before 3 pm in SCLC patients resulted in hazard ratios of 0.48 and 0.37 for improved outcomes. Cancer immunotherapy works better earlier in the day, as supported by recent studies.
What is the OS benefit of adagrasib in KRAS-mutated tumors?
Adagrasib demonstrated an overall survival of 14.7 months in mutated solid tumors. It shows promise in treating KRAS-mutated cancers.
How does AI predict SCLC treatment response?
The AI tool PhenopyCell predicts whether aggressive SCLC will respond to treatment. It uses advanced analytics for better patient selection in this hard-to-treat cancer.
What progress is there in mRNA cancer vaccines?
mRNA therapeutic vaccines are in early development, including personalized options from JHU and Optimus Phase 1. Scientists are advancing vaccines targeting cancer-specific antigens for immunotherapy.
Prostate VIR-5500/PEACE-3 strong; PORTEC-4a endometrial; CRISPR CAR-T BTD; melanoma Cu-patch/H&N proton/RCC belzu/LITESPARK-022 Ph3 adj ccRCC; HER2 KN026; TILs anorectal/GBM; RIBOTAC RNA preclinical; dual HIF+IO complete rem mice; durva+FLOT gastric EFS; NSCLC ADC amivantamab 85%ORR + gotistobart CTLA4 Ph3 squamous OS NR ORR20% + SCLC IO timing pre-3pm HR0.48/0.37 + AI PhenopyCell predict; HCC EMERALD-3 PFS win; KRAS adagrasib OS14.7m; MM MajesTEC-3 teclistamab+dara HR0.17/83%3y + IsKia NDMM MRD77%; PANOVA-4 TTFields panc; TNBC nano; mRNA therapeutic vaccines early dev JHU personalized; Optimus Ph1; P3s/AI/access priorities.